Release Date: 09/24/2014
Researchers at Women & Infants Hospital of Rhode Island recently presented research demonstrating a connection between gynecologic cancer and an increased prevalence of high-risk human papillomavirus (HPV) infection.
The project, led by Katina Robison, MD, of the Program in Women’s Oncology, is entitled “Increased Prevalence of Abnormal Anal Cytology and High-Risk HPV in Women with a History of Lower Genital Tract Dysplasia or Neoplasia” and was presented at the 2014 HPV Conference in Seattle.
“HPV is associated with anal cancer, which is more common among women. In 2014 alone, there were 7,200 cases of anal cancer noted and 4,500 of them are women. We believe that women with HPV would benefit greatly from routine anal cancer screening,” concludes Dr. Robison, who is also an assistant professor and director of colposcopy at The Warren Alpert Medical School of Brown University.
Anal cancer screening is routinely performed using anal cytology in HIV positive men and women, as well as in men having sex with men. Knowing that anal cancer is five times more likely in women with a history of cervical, vaginal or vulvar cancer, which are all linked to HPV, Robison wanted to evaluate the feasibility of screening HIV negative women with anal cytology and HPV testing.
The research – conducted from December 2012 to February 2014 – examined 273 women recruited through Women & Infants’ outpatient clinics. Anal cytology and HPV genotyping were performed. All women with abnormal anal cytology were referred for high-resolution anoscopy. Biopsies were also conducted at the discretion of the colorectal surgeon.
The 273 women were divided into two groups – the “exposed group” who had a history of cervical, vaginal or vulvar cancer, and the “unexposed group” who had no history of cancer, dysplasia or abnormal Pap smears. Of those, 40 percent of the exposed group and 21.7 percent of the unexposed group were found to have abnormal anal cytology. In the exposed group, 20.8 percent were found to have high-risk HPV, but only 1.2 percent of the unexposed group.
The study also included the work of other scientists affiliated with Women & Infants. Listed as co-authors were: Beth Cronin, MD; Melissa Clark, MD; Christine Luis, MS; Paul DiSilvestro, MD; Steven Schecter, MD; Latha Pisharodi, MD; Christina Raker, ScD; Amy Bregar, MD; and Joel Palefsky, MD.
Women interested in making an appointment with Dr. Robison or other providers with the Program in Women’s Oncology at Women & Infants can call (401) 453-7520.
About Women & Infants Hospital
Women & Infants and Brown offer fellowship programs in gynecologic oncology, maternal-fetal medicine, urogynecology and reconstructive pelvic surgery, neonatal-perinatal medicine, pediatric and perinatal pathology, gynecologic pathology and cytopathology, and reproductive endocrinology and infertility. It is home to the nation’s first mother-baby perinatal psychiatric partial hospital, as well as the nation’s only fellowship program in obstetric medicine.
Women & Infants has been designated as a Breast Imaging Center of Excellence by the American College of Radiography; a Center of Excellence in Minimally Invasive Gynecology; a Center of Biomedical Research Excellence by the National Institutes of Health (NIH); and a Neonatal Resource Services Center of Excellence. It is one of the largest and most prestigious research facilities in high risk and normal obstetrics, gynecology and newborn pediatrics in the nation, and is a member of the National Cancer Institute’s Gynecologic Oncology Group and the Pelvic Floor Disorders Network.